Shares of Silk Road Medical Inc (NASDAQ:SILK) have been assigned a consensus broker rating score of 1.50 (Buy) from the four brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a hold rating and three have issued a strong buy rating on the company.
Analysts have set a 1-year consensus target price of $49.67 for the company and are expecting that the company will post ($0.28) earnings per share for the current quarter, according to Zacks. Zacks has also given Silk Road Medical an industry rank of 104 out of 256 based on the ratings given to its competitors.
SILK has been the topic of several recent research reports. JPMorgan Chase & Co. set a €118.00 ($137.21) price objective on shares of Deutsche Boerse and gave the company a “neutral” rating in a research report on Monday, April 29th. Bank of America reiterated a “buy” rating and issued a $420.00 price objective (up from $400.00) on shares of Lendingtree in a research report on Monday, April 29th. BMO Capital Markets lifted their price objective on shares of Discover Financial Services to $92.00 and gave the company a “market perform” rating in a research report on Monday, April 29th. Finally, Stifel Nicolaus reiterated a “hold” rating on shares of NEXT in a research report on Monday, April 29th.
Silk Road Medical (NASDAQ:SILK) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($7.03) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($6.67). The company had revenue of $12.77 million for the quarter, compared to analysts’ expectations of $12.28 million. As a group, sell-side analysts anticipate that Silk Road Medical will post -1.75 EPS for the current fiscal year.
A hedge fund recently bought a new stake in Silk Road Medical stock. Norwest Venture Partners Xiii LP acquired a new stake in Silk Road Medical Inc (NASDAQ:SILK) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 2,461,974 shares of the company’s stock, valued at approximately $119,307,000. Silk Road Medical comprises about 100.0% of Norwest Venture Partners Xiii LP’s investment portfolio, making the stock its biggest holding. Norwest Venture Partners Xiii LP owned about 8.03% of Silk Road Medical at the end of the most recent quarter.
About Silk Road Medical
Silk Road Medical, Inc operates as a medical device company in the United States. It offers ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent with clinical data regarding lasting safety outcomes; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices.
Recommended Story: Capital Gains Distribution
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Silk Road Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silk Road Medical and related companies with MarketBeat.com's FREE daily email newsletter.